Functional respiratory imaging specialist FLUIDDA has announced a new research collaboration with a team at the University of California, San Francisco led by Professor John Fahy that will use FLUIDDA technology “to understand the effects of pathologic mucus on lung function and on the deposition patterns of inhaled therapeutics.”
FLUIDDA CEO Jan De Backer said, “We are very excited to embark upon this collaboration with the renowned group of Dr. Fahy. Using our imaging technology to understand the role of mucus in the disease process of asthmatic patients is a challenging but highly interesting topic. Together we believe we can make significant progress in the development of better therapies for patients suffering from lung diseases.”
In July 2017, FLUIDDA announced that it was launching an FDA biomarker approval initiative, with plans to submit briefing packages for COPD, idiopathic pulmonary fibrosis, lung transplantation, and bioequivalence.
Read the FLUIDDA press release.